Genome-wide surveillance of mismatched alleles for graft-versus-host disease in stem cell transplantation.

PubWeight™: 1.39‹?› | Rank: Top 5%

🔗 View Article (PMID 26432889)

Published in Blood on October 02, 2015

Authors

Aiko Sato-Otsubo1, Yasuhito Nannya2, Koichi Kashiwase3, Makoto Onizuka4, Fumihiro Azuma3, Yoshiki Akatsuka5, Yasuko Ogino6, Masahiro Satake3, Masashi Sanada1, Shigeru Chiba7, Hiroh Saji8, Hidetoshi Inoko4, Giulia C Kennedy9, Ken Yamamoto10, Satoko Morishima11, Yasuo Morishima12, Yoshihisa Kodera13, Takehiko Sasazuki14, Seishi Ogawa1, Japan Marrow Donor Program

Author Affiliations

1: Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Bunkyō-ku, Tokyo, Japan; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Tokyo, Japan; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;
2: Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Tokyo, Japan;
3: Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan;
4: Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan;
5: Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan; Aichi Cancer Center Research Institute, Nagoya, Japan;
6: Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Bunkyō-ku, Tokyo, Japan; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Tokyo, Japan;
7: Department of Hematology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan;
8: HLA Foundation Laboratory, Kyoto, Japan;
9: Affymetrix, Santa Clara, California;
10: Medical Institute of Bioregulation, Kyusyu University, Fukuoka, Japan;
11: Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan;
12: Aichi Cancer Center Research Institute, Nagoya, Japan;
13: Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University, Nagoya, Japan; and.
14: Institute for Advanced Study, Kyusyu University, Fukuoka, Japan.

Articles by these authors

High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood (2007) 2.46

Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica (2008) 1.79

Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood (2014) 1.60

HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood (2008) 1.44

Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant (2007) 1.26

A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PLoS One (2011) 1.20

Impact of highly conserved HLA haplotype on acute graft-versus-host disease. Blood (2010) 1.19

Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood (2011) 1.10

Possible association between obesity and posttransplantation complications including infectious diseases and acute graft-versus-host disease. Biol Blood Marrow Transplant (2009) 1.08

Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant (2008) 0.99

Single nucleotide polymorphisms and outcome risk in unrelated mismatched hematopoietic stem cell transplantation: an exploration study. Blood (2012) 0.98

Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor. Biol Blood Marrow Transplant (2005) 0.94

Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood (2011) 0.92

A single nucleotide polymorphism of IL-17 gene in the recipient is associated with acute GVHD after HLA-matched unrelated BMT. Bone Marrow Transplant (2011) 0.92

NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica (2009) 0.90

Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant (2007) 0.89

Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Br J Haematol (2007) 0.87

High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation. Haematologica (2016) 0.85

Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelated bone marrow transplantation for myeloid malignancies. PLoS One (2011) 0.80

A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies. Bone Marrow Transplant (2010) 0.77

M-CSF attenuates severity of chronic GVHD after unrelated BMT. Bone Marrow Transplant (2011) 0.77

Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program. Blood (2003) 0.76

The recipient CXCL10 + 1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation. Clin Immunol (2012) 0.76

Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2012) 0.75

Toll-like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies. Transpl Immunol (2016) 0.75